Pharmacological profiling of a berbamine derivative for lymphoma treatment.

Authors:
Xu S; Wu S; Zhang M; Xie J; Lin M and 19 more

Journal:
Blood Adv

Publication Year: 2024

DOI:
10.1182/bloodadvances.2023010873

PMCID:
PMC10824694

PMID:
37967356

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Blood Adv

Abbreviation: Blood Adv

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody tre…
Wang L; Leach V; Muthusamy N and 2 more (2024) - Transparency Score: 3/6
A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell …
Shree T; Haebe S; Czerwinski DK and 15 more (2024) - Transparency Score: 5/6
A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA…
Abou-Ismail MY; Zhang C; Presson AP and 28 more (2024) - Transparency Score: 3/6
Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic.
Banerjee R; Poh C; Hirayama AV and 9 more (2024) - Transparency Score: 3/6
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymp…
Short NJ; Jabbour E; Jain N and 20 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"the rna sequencing data are deposited in the gene expression omnibus database (accession number gse245491 )."

Code Sharing
Evidence found in paper:

"Conflict-of-interest disclosure: The authors declare no competing financial interests."

Evidence found in paper:

"W.H. is supported by 10.13039/100000054National Cancer Institute award number NCI 2R01CA139158 and 10.13039/100000062National Institute of Diabetes and Digestive and Kidney Diseases award number NIDDK R01DK124627. Research reported in this publication was also supported by 10.13039/100000054National Cancer Institute of the 10.13039/100000002National Institutes of Health award number P30CA33572 and City of Hope Integrated Drug Development Venture."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025